More local health care insiders book big stock profits

HCA, AmSurg, Acadia execs take home $7M+
Aug 12, 2015 7:17 AM

Analyst action: AmSurg, Delek

Paula Torch at Avondale Partners really likes the look of AmSurg following the surgery center and physician services company's second-quarter profit report. The integration of the Sheridan physician services business is running smoothly, she says, while organic growth is topping expectations and the acquisition pipeline is solid. In response, Torch has hiked her price target for AmSurg (Ticker: AMSG) all the way to $90 from $74. After popping this week on the heels of the Q2 report, AmSurg is changing hands Thursday morning at almost $84.

Given the 1H performance and Management's execution thus far, 2015 guidance could still wind up being conservative as we expect strong ASC and PS metrics to continue. Furthermore, we feel more comfortable with AMSG's cross-selling initiatives, which are above internal expectations and its ability to execute on JV partnerships.

RBC Capital Markets analyst Brad Heffern has reiterated his 'outperform' rating on shares of Delek US Holdings in the wake of the company's Q2 earnings report. But he has lifted his price target for the Brentwood-based company to $44 from $42. That leaves more than 25 percent of upside from where Delek (Ticker: DK) is changing hands Thursday morning.

Aug 6, 2015 11:15 AM

Earnings wrap: Acadia, AmSurg

Behavioral health company raises guidance, surgical centers owner beats on EPS
Aug 5, 2015 6:57 AM

Avondale analyst sees upside for AmSurg

Avondale Partners analyst Paula Torch said she expects AmSurg to report second quarter earnings in-line with expectations with potential for upside. Torch also said adjusted earnings per share could exceed analysts' expectation of 85 cents, which is above the ambulatory surgery center's guidance range of 81 cents to 84 cents.

AmSurg has completed six acquisitions this year. "While we continue to believe the pipeline is robust, we look for more color on the pace and ability to meet or exceed $200 million in capital spend on M&A in 2015," Torch said in a report.

Shares of AmSurg (Ticker: AMSG) were down 1 percent to $68.27. Year to date, they're up almost 25 percent.

Jul 22, 2015 7:05 AM

AmSurg division acquires anesthesia practice

Physician services arm Sheridan acquires more than 25 anesthesia providers
Jul 2, 2015 12:00 PM

Local health care stocks pop on SCOTUS decision

Investors bid up shares of many Middle Tennessee health care companies Thursday morning after the U.S. Supreme Court upheld subsidies for people using the federal health insurance marketplace. At about 9:30 a.m., almost a half hour after the justices issued their opinion, both HCA Holdings and Community Health Systems were up about 8 percent — both to all-time highs — while fellow hospital operator LifePoint Health was up 5 percent. Other publicly held locals such as behavioral health plays Acadia Healthcare and AAC Holdings were up slightly. You can track all their movements today here.

 

Jun 25, 2015 9:34 AM

Analyst action: Hospitals, AmSurg

Analyst Sarah James has formally begun covering shares of Nashville's big three hospital operators as well as other prominent health care players. She rates both HCA Holdings and Community Health Systems at 'outperform,' saying investors will benefit from, among other things, the growth of HCA's Parallon support services unit and CHS' potential for margin expansion. James isn't as bullish on the prospects of LifePoint Health, which she has given a 'neutral' rating.

Over at Goldman Sachs, analysts have launched coverage of Amsurg with a 'buy' rating and $81 target. That's 17 percent above where AmSurg (Ticker: AMSG) closed Wednesday trading.

Jun 11, 2015 7:39 AM

Avondale Partners raises price target for AmSurg

Avondale Partners analyst Paula Torch has raised her price target for Nashville-based AmSurg to $74 from $69.

The firm has maintained its 'market outperform' for the company, saying its raised guidance for revenues in a range of $2.46 billion to $2.48 billion could be conservative.

"[AmSurg] is executing on its JV partnerships, cross-selling initiatives, and we believe the pipeline for acquisitions remains plentiful," Torch said in a report issued Wednesday.

Shares of AmSurg (Ticker: AMSG) were up to $64.75 Thursday morning. Year to date, they've climbed 18 percent.

May 7, 2015 11:15 AM

Earnings wrap: CHS, AmSurg

Hospital owner reverses prior-year loss, surgery center operator raises guidance
May 6, 2015 6:52 AM

Analyst action: AmSurg, Delek Logistics

Shares of AmSurg jumped more than 4 percent Thursday — and closed within 3 percent of their all-time high — after analysts at Stephens launched coverage of the ambulatory surgery and physician services company with an 'overweight' rating at $77 price target. That last number is the highest on the Street and $10 above the median target. It leaves more than 20 percent of upside for AmSurg (Ticker: AMSG), which already has climbed 16 percent year to date.

The limited partner units of Delek Logistics Partners (Ticker: DKL) fell about 3 percent to $41.59 Thursday after Barclays analyst Richard Gross reiterated his 'hold' rating. Gross has a $45 price target for the company, which Wells Fargo Securities' Roger Read and Lauren Hendrix say would benefit big time from any deal between Delek US Holdings and Alon USA Energy.

Apr 3, 2015 6:52 AM